 SEATTLE, May 18, 2022 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL. 